Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors.
Journal: Cancer discovery
Published: February 05, 2026
COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.
Journal: Cancer immunology, immunotherapy : CII
Published: September 13, 2020
Therapeutic Targeting of Checkpoint Receptors within the DNAM1 Axis.
Journal: Cancer discovery
Published: August 27, 2020
PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia
Journal: Haematologica
Published: May 19, 2020
PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function.
Journal: Cancer immunology research
Published: July 05, 2018
Showing 1-5 of 5
Last Updated: 09/26/2026